Protocols
2 protocol(s) meet the specified criteria
Drug: ERLOTINIB
Protocol No.TitleStatus
A081105-CIRBRandomized Double Blind Placebo Controlled Study of Erlotinib or Placebo In Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Open
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open